Is ROCKET PHARMACEUTICALS, INC. (RCKT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.2% / 30% | 39.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 5.2% / 33% | 39.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 7.5% / 33% | 57.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.2% / 33% | 39.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 7.5% / 33% | 57.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -60.3% | |
| Return on Assets (ROA) | -33.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$190M |
| Free Cash Flow | -$190M |
| Total Debt | $25M |
| Debt-to-Equity | 9.0 |
| Current Ratio | 6.4 |
| Total Assets | $330M |
Price & Trading
| Last Close | $4.69 |
| 50-Day MA | $4.04 |
| 200-Day MA | $3.46 |
| Avg Volume | 2.6M |
| Beta | 0.4 |
|
52-Week Range
$2.19
| |
About ROCKET PHARMACEUTICALS, INC. (RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ROCKET PHARMACEUTICALS, INC. (RCKT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ROCKET PHARMACEUTICALS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ROCKET PHARMACEUTICALS, INC.'s debt ratio?
ROCKET PHARMACEUTICALS, INC.'s debt ratio is 5.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.
What are ROCKET PHARMACEUTICALS, INC.'s key financial metrics?
ROCKET PHARMACEUTICALS, INC. has a market capitalization of $409M. Return on equity stands at -60.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.